Brief: Inventiva FY Revenue Up At EUR 4.2 Mln

Inventiva SA

15/02/2022 08:35

Feb 15 (Reuters) - INVENTIVA SA  IVAA.PA :
    * ANNOUNCED ON MONDAY FY REVENUE EUR 4.2 MLN VS EUR 0.4 MLN
YR AGO
    * END-DECE CASH POSITION EUR 95.4 MLN VS EUR 113.0 MLN YR
AGO
    * EXPECTS ACTIVATION OF FIRST CLINICAL SITES FOR PHASE IIA
COMBINATION TRIAL WITH LANIFIBRANOR AND SGLT2 INHIBITOR
EMPAGLIFLOZIN IN PATIENTS WITH NASH AND T2D – PLANNED FOR H1
2022
    * EXPECTS LAST PATIENT FIRST VISIT OF THE NATIV3 PHASE III
CLINICAL TRIAL EVALUATING LANIFIBRANOR IN NASH – PLANNED FOR H2
2022
    * EXPECTS PUBLICATION OF THE RESULTS OF THE PHASE II
CLINICAL
TRIAL EVALUATING LANIFIBRANOR FOR THE TREATMENT OF NAFLD IN
PATIENTS WITH T2D – PLANNED FOR H2 2022
    * EXPECTS STRATEGY UPDATE ON THE DEVELOPMENT OF ODIPARCIL –
PLANNED FOR 2022

    
 Source text: https://bit.ly/3rOe5Vi
 Further company coverage:  IVAA.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))